Recent Updates — TELO

Telomir Pharmaceuticals raised approximately $5.6 million through a private placement of 4,843,300 shares of common stock at $1.16 per share. The transaction closed on October 5, 2026, and includes an additional $1.0 million investment from existing significant shareholder John Paul DeJoria. Proceeds will primarily support the clinical development of Telomir-Zn in triple-negative breast cancer and general corporate purposes. Alexander Capital acted as placement agent for the offering.

Telomir Pharmaceuticals, Inc. announced the peer-reviewed publication of preclinical data for Telomir-Zn in Biomedicine & Pharmacotherapy, demonstrating dose-dependent improvements in glucose homeostasis and insulin resistance in a zebrafish model of Type 2 diabetes. The findings support the mechanism of action for Telomir-Zn, which has received FDA IND clearance for a Phase 1/2 clinical trial in triple-negative breast cancer. Telomir Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing clinical-stage lead programs.